

PRESS RELEASE

Paris, on May 5, 2020

Parquest Capital sells homecare specialist Homeperf to Sapio, Italian leader in home care services and medical gases production

Parquest Capital announces the sale of its majority stake in Homeperf, one of the French leaders in homecare services, to Sapio, an Italian group leader in industrial and medical gases production, as well as in homecare services. This sale takes place five years after its investment. Over the period, the group has specialized, structured and strengthened itself in an increasingly competitive market to reach 52 million euros of revenues at the end of 2019.

Wishing to continue supporting Homeperf in its new projects, Parquest Capital and its partners (Vivalto - Daniel Caille's personal holding company -, BNP Paribas Développement and Arkéa Capital) are reinvesting by taking a significant minority stake along with Sapio.

Created in 1997 and based in Aix-en-Provence, Homeperf is a brand strongly established in France through its national network of 37 agencies and 360 employees. Operating in the homecare market, it specialises in patient treated at home with infusion, artificial nutrition, insulin therapy and respiratory care.

The acquisition of Homeperf represents for Sapio the opportunity to build on a solid base to give a new impetus to its development on the French market and to strengthen its position as an independent European player on the home healthcare market. With a turnover of more than 550 million euros, Sapio employs 1,800 people, 1,000 of whom work in Italy. The group is also present in Germany, France, Spain, Turkey and Slovenia.

Mario Paterlini, CEO of Sapio and new president of Homeperf: *"This acquisition marks a very important step, as France is Europe's leading home care market, a market that is constantly growing in value. For our growth strategy, it was therefore decisive to strengthen our presence: Homeperf represented a unique development opportunity. I would like to thank the group of investors who made this operation possible. Our goal now is to become one of the leading national players, with a strong brand, highly qualified staff, an extensive presence in the territory and an excellent reputation. "*

Recognized expertise in the health sector

This sale, which comes a few months after the sale of Groupe 5 Santé to Korian, illustrates Parquest Capital's expertise in the healthcare sector. Its team is recognized for its expertise in this sector, with nearly 15 years of experience in supporting the development of companies that have become leaders in their markets, particularly in the field of healthcare services, both at home and in institutions, with success stories such as Vivalto Santé, Unither Pharmaceuticals, Homeperf and the 5 Santé group of private clinics and follow-up care.

"We have been very pleased to support Homeperf's development over these five years in an activity that today more than ever demonstrates its importance and a sector in which Parquest Capital has made a major strategic focus. The company's success story, which began more than twenty years ago, will be able to continue and accelerate with an industrial partner who will give it the means to take it to the next level", says Denis Le Chevallier, Managing Partner of Parquest Capital.

Assignors /Reinvestors:

Parquest Capital (Denis Le Chevallier, Laurence Bouttier, Vincent Warlop)

Vivalto (Daniel Caille)

BNP Paribas Développement (Yannick Carré)

Arkéa Capital (Thomas Trideau)

M&A advisory: Rothschild (Pierpaolo Carpinelli, Elena Coluccelli, Nicolas Aftimos, Côme Sesboue)

Legal advisory: Goodwin (Thomas Maitrejean, Edouard Baladès, Adrien Paturaud)

Financial due diligence: 8 Advisory (Katia Wagner, Justine Roux)

Buyers:

Sapio (Mario Paterlini, Francesca Paludetti, Massimo Caviezel, Carmen Panzeri))

M&A advisory: Lincoln (François Rispoli, Louis de Kergos, Francesco Silva, Eugenio Orlando)

Legal advisory: GIDE (Christophe Eck, Armelle Royer, Clarisse Thirion), NCTM (Michele Motta, Mario Bonferroni)

Financial and tax due diligence: EY (Finance: Marion Lassus Pigat, Fany Krieger, Marco Ginnasi / Tax: Sandrine Gobaut, Laurie Soyer, Quirino Walter Imbimbo, Felice Paglia)

About Parquest Capital

Created in 2002, Parquest Capital is a recognized private equity player in France in the mid-market segment. Since its creation, Parquest Capital has made 28 investments with a philosophy of providing long-term support for ambitious growth projects, working along with management teams. In 2017, Parquest Capital successfully completed the raising of its second fund since it became independent from ING Group in 2014, for a total of €310 million.

For further information: www.parquest.fr

About BNP Paribas Développement

BNP Paribas Développement has been running a private equity business dedicated to growth companies for more than 20 years. A wholly owned subsidiary of the BNP Paribas Group, BNP Paribas Développement invests the Bank's equity directly in long-term projects with a focus on the growth and development of companies. The objective is to invest in companies with significant development, alongside entrepreneurs surrounded by talented and ambitious management teams. BNP P Développement has a portfolio of investments split between more than 400 companies representing more than €1,000 million invested.

For further information: www.bnpparibasdeveloppement.com

About Arkéa Capital

As a minority shareholder, Arkéa Capital supports companies, from start-ups to mid-sized companies, at all stages of their development, while maintaining the independence of the decision-making centers. A subsidiary of the Arkéa group dedicated to private equity activities, Arkéa Capital has been active for more than 30 years in all business sectors throughout France, through six regional offices and a team of experts. It supports companies and their managers over the long term through five complementary investment vehicles: Arkéa Capital Investissement, Arkéa Capital Partenaire, Arkéa Capital Managers, West Web Valley and We Positive Invest. Arkéa Capital is present in nearly one hundred companies and currently manages an equity capital volume of approximately €1 billion.

For further information: www.arkea-capital.com

About Gruppo Sapio

The Sapio Group, founded in 1922 and based in Monza, operates in the industrial and medical gases sector throughout Italy and in the home healthcare sector, as well as in France, Germany, Slovenia, Turkey and Spain.

With a turnover of 550 million euros and 1800 employees (2019), the company produces, develops and markets gases, innovative technologies and integrated services for the industrial sector. Technical gases are used in all production sectors, from the food industry to the environment and energy, from pharmaceutical chemistry to electronics, from mechanics and metallurgy to glass and cement. In the health care sector, the production and supply of medical gases for hospitals and health care institutions is complemented by the supply of medical devices, integrated home care and palliative care. Sapio is present in the biotechnology sector with a biological resource center capable of providing complete solutions for the conservation of biological material, laboratory services and DNA sequencing to public and private research institutes (hospitals, universities, clinics), biotechnology and pharmaceutical companies.

For further information: www.grupposapio.it

Media contact:

Capmot

Jean-Philippe Mocci

+ 33 (0)1 81 70 96 33 | + 33 (0)6 71 91 18 83

jpmocci@capmot.com